Enhanced thrombin generation in normal and hypertensive pregnancy.
about
Tissue factor and its natural inhibitor in pre-eclampsia and SGAThrombophilia and Recurrent Pregnancy Loss: Is heparin still the drug of choice?Pregnancy-specific glycoproteins bind integrin αIIbβ3 and inhibit the platelet-fibrinogen interactionCerebrovascular Disease in Pregnancy.Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia.Syncytiotrophoblast microvesicles released from pre-eclampsia placentae exhibit increased tissue factor activity.Plasma concentrations of angiogenic/anti-angiogenic factors have prognostic value in women presenting with suspected preeclampsia to the obstetrical triage area: a prospective study.Natural coagulation inhibitors and active protein c resistance in preeclampsia.Placental vascular pathology and increased thrombin generation as mechanisms of disease in obstetrical syndromes.Pyelonephritis during pregnancy: a cause for an acquired deficiency of protein Z.Endocan, a putative endothelial cell marker, is elevated in preeclampsia, decreased in acute pyelonephritis, and unchanged in other obstetrical syndromesAn anticoagulant dermatan sulfate proteoglycan circulates in the pregnant woman and her fetus.Recurrent pregnancy loss and thrombophiliaPhysiological changes in hematological parameters during pregnancy.Changes in amniotic fluid concentration of thrombin-antithrombin III complexes in patients with preterm labor: evidence of an increased thrombin generation.Preeclampsia is associated with low concentrations of protein Z.Plasma protein Z concentrations in pregnant women with idiopathic intrauterine bleeding and in women with spontaneous preterm labor.Long-term alterations in maternal plasma proteome after sFlt1-induced preeclampsia in mice.Pregnancy and thrombophilia.Over-expression of the thrombin receptor (PAR-1) in the placenta in preeclampsia: a mechanism for the intersection of coagulation and inflammation.What is new in the 2006 ACC/AHA guidelines on valvular heart disease?Clinical features of isolated gestational proteinuria progressing to pre-eclampsia: retrospective observational study.Role of Plasminogen Activator Inhibitor Type 1 in Pathologies of Female Reproductive Diseases.Is plasminogen activator inhibitor-1 a physiological bottleneck bridging major depressive disorder and cardiovascular disease?Tissue factor activity in women with preeclampsia or SGA: a potential explanation for the excessive thrombin generation in these syndromes.The pattern and magnitude of "in vivo thrombin generation" differ in women with preeclampsia and in those with SGA fetuses without preeclampsia.The levels of five markers of hemostasis and endothelial status at different stages of normotensive pregnancy.Characterization of five marker levels of the hemostatic system and endothelial status in normotensive pregnancy and pre-eclampsia.Perfusion with magnesium sulfate increases sFlt-1 secretion only in the fetal side of placenta of women with preeclampsia.The effect of magnesium sulfate treatment on blood biochemistry and bleeding time in patients with severe preeclampsia.Blood laboratory testing for early prediction of preeclampsia: chasing the finish line or at the starting blocks?Coagulation and plasma fibronectin parameters in HELLP syndrome.Part 2: ultrastructural changes of fibrin networks during three phases of pregnancy: a qualitative investigation.Placental nitric oxide synthase (NOS) activity and nitric oxide (NO) production in normal pregnancy, pre-eclampsia and eclampsia.The profiles of soluble adhesion molecules in the "great obstetrical syndromes".Changes in the plasma levels of protein C system parameters in pregnancy.Maternal plasma fetuin-A concentration is lower in patients who subsequently developed preterm preeclampsia than in uncomplicated pregnancy: a longitudinal study.Activation of coagulation system in preterm labor and preterm premature rupture of membranesElevated levels of serum nitrate, a stable end product of nitric oxide, in women with pre-eclampsiaEvidence of maternal platelet activation, excessive thrombin generation, and high amniotic fluid tissue factor immunoreactivity and functional activity in patients with fetal death
P2860
Q24323351-70085754-7D2A-4DA5-BAE7-9A83FF2BCBFAQ26864495-8BD22A37-A0BC-4999-849B-1C9D969C9A6AQ28595015-3AF7182C-57A2-449B-9CD6-654A10B3F4B0Q33348222-97E1BD8D-EEB6-4C12-BD39-56F098741932Q33863973-FF2BCBBD-0E89-4F5F-9838-9F344F4DED15Q34056273-7809132B-1C51-4C3E-A204-49DB9BBEBDDFQ34119026-CD925405-126A-4142-9C4C-1AA8C2499CF8Q34393988-214EDD26-8E0F-4EF0-9AC9-EE9FB3EF8E37Q34568696-8A685A21-AD05-47FE-BC07-A7619B6D9B56Q35104787-8E2859FC-9173-4C05-91A8-3AA80136AFD5Q35547367-14C1A7EB-0758-4FC3-B08B-C7A8A157EDD6Q35596833-12B4D5BB-DF1E-4F0E-A046-69E7B654B2B6Q35820958-859C1853-AA47-4798-9E8F-9C4DD6CA1C8BQ36173723-0738FE89-ED68-4F58-B34D-72ACECDEAA24Q36487783-F133F755-AAB3-42CD-9170-DE89C5CD7521Q36670687-4F5D17E8-47CA-4028-AFBB-BB002614ADDDQ36678753-07640E68-243F-4FF3-A63E-F5ADD410767AQ36799569-8DD38273-B311-4EC0-BC72-669164412BD2Q36867306-DFCED922-A39A-440F-9EB2-9A2D9327C13AQ37039719-DB78EEBD-5588-407E-8975-9A9828A03761Q37139917-2E9C6697-601B-4072-BBEC-2717DEE61266Q37718651-863B5FCE-37B1-4E53-A00B-D2106647ABCBQ38649391-C84F7737-3234-44E6-8E2D-6868EE203F98Q38849673-CF863639-4A9F-46C0-A3CB-D83C4ACECBF4Q40196259-2171561C-1A68-49D3-90CE-62920828DD00Q40230103-E2081C7D-CFFE-4907-9A06-C2BC1C2CB585Q43967083-BCC366B7-9D78-4E92-A1A1-3ACE4C72F58AQ44235072-BF5801C0-F757-4F83-BE2F-94C152E4E250Q44314054-373803D5-4FDF-48A8-B717-80AB931C644FQ45917062-42C2F4C5-411E-4F54-B7AA-4CE320FACCE9Q46306526-EB15728A-ADC6-45CC-8673-BD0E2B8E2712Q46362075-3FEF3C13-414B-401F-9856-3D99F5DF8C20Q46606458-55574B52-76F6-4A45-8D41-55CC5FBABC22Q46785900-901CD3D3-2891-44CB-B855-C345A74203D8Q50102668-82AB55D1-6478-45F8-87F7-BE732C495585Q53905103-1B33F631-F4FF-4117-8CDD-55938230D572Q55004295-D6218FED-28B1-47EB-9257-B7DABEADD5ADQ57081391-84315010-AD06-4FF3-A614-62628F16D9E8Q57208323-2B18E978-3CDD-4437-834C-08B7916C8E58Q58417742-AE41C004-73A5-4061-9F74-65A84B3974C5
P2860
Enhanced thrombin generation in normal and hypertensive pregnancy.
description
1989 nî lūn-bûn
@nan
1989 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
Enhanced thrombin generation in normal and hypertensive pregnancy.
@ast
Enhanced thrombin generation in normal and hypertensive pregnancy.
@en
Enhanced thrombin generation in normal and hypertensive pregnancy.
@nl
type
label
Enhanced thrombin generation in normal and hypertensive pregnancy.
@ast
Enhanced thrombin generation in normal and hypertensive pregnancy.
@en
Enhanced thrombin generation in normal and hypertensive pregnancy.
@nl
prefLabel
Enhanced thrombin generation in normal and hypertensive pregnancy.
@ast
Enhanced thrombin generation in normal and hypertensive pregnancy.
@en
Enhanced thrombin generation in normal and hypertensive pregnancy.
@nl
P2093
P1476
Enhanced thrombin generation in normal and hypertensive pregnancy.
@en
P2093
P304
P356
10.1016/0002-9378(89)90096-3
P407
P577
1989-01-01T00:00:00Z